Opendata, web and dolomites

GAIT

From symptom relief to disease modifying allergy treatment with Glycan-Allergen Immunotherapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GAIT project word cloud

Explore the words cloud of the GAIT project. It provides you a very rough idea of what is the project "GAIT" about.

cured    attempts    global    20    pharmaceutical    placebo    market    corticosteroids    sme    followed    suited    mechanisms    glycans    treat    inducing    antihistamines    harm    therapy    immunotherapy    annual    alarming    proprietary    refine    patient    allergens    shown    recognition    chronic    protection    safe    human    protein    pollen    develops    profitability    ait    curative    vivo    modifying    decongestants    dose    life    risks    dc4u    medicine    substances    course    generation    dominated    replace    tolerance    ipr    alleviating    pace    responsible    instead    license    healthy    licensing    incorporated    symptom    allergy    clinical    business    investors    disease    grass    prevalence    elaborated    plan    severe    endogenous    negotiations    strategy    plans    elaborate    healthcare    gp    treatment    initialize    iia    company    underlying    sia    individuals    allergen    doses    relieving    immune    medical    trials    efficacy    worldwide    self    characterised    therapeutics    extract    diseases   

Project "GAIT" data sheet

The following table provides information about the project.

Coordinator
DC4U 

Organization address
address: DE CORRIDOR 21E
city: BREUKELEN
postcode: 3621 ZA
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website http://www.dc4u-technologies.nl
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-03-01   to  2017-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DC4U NL (BREUKELEN) coordinator 50˙000.00

Map

 Project objective

The annual increase in prevalence of allergy related diseases develops at an alarming pace worldwide. Responsible disease mechanisms are characterised by unwanted immune responses to substances which do not harm healthy individuals. The allergy therapeutics market is now dominated by symptom alleviating antihistamines, decongestants and corticosteroids. The main patient need is to get cured with a disease modifying medicine instead of the chronic use of symptom relieving products. Allergen-specific Immunotherapy (AIT) attempts to treat the underlying cause by inducing allergen-specific immune tolerance. However, currently used AIT with high doses of extract is not effective enough (only 20% better than placebo), risks severe side effects and requires 5 years of treatment.

DC4U is developing a new generation of disease modifying allergy treatment with the potential to replace symptom relieving products and current AIT. We apply a new and unique technology to present allergens to the immune system as being SELF and SAFE, using glycans as endogenous human protein recognition elements. Our lead product, “sia-GP”, is a grass pollen allergy treatment for life long protection, achieved in a short treatment course. DC4U has shown highly promising in-vivo dose-response efficacy results and will further develop this proprietary product up to and including Phase IIa clinical trials. This will be followed by out-licensing to a pharmaceutical company. Effective curative tolerance inducing therapy will contribute to global medical needs and reduction of healthcare costs.

In this SME-1 we will elaborate and refine our clinical plans, IPR strategy, market analysis and profitability analysis. Furthermore, we will initialize discussions and negotiations with several possible investors and licensing partners. All will be incorporated in an elaborated European business plan with best suited to out-license sia-GP after Phase IIa clinical trials.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GAIT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GAIT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More  

IcoCell (2015)

IcoCell− Chassis for Enhanced Mammalian Cell Line Development and Engineering

Read More